tacrine has been researched along with myricetin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Chalupova, K; Gorecki, L; Hepnarova, V; Hrabinova, M; Hroudova, J; Janockova, J; Jun, D; Korabecny, J; Kristofikova, Z; Kucera, T; Kunes, J; Mezeiova, E; Muckova, L; Prchal, L; Soukup, O | 1 |
2 other study(ies) available for tacrine and myricetin
| Article | Year |
|---|---|
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Huprine Y - Tryptophan heterodimers with potential implication to Alzheimer's disease treatment.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Tryptophan | 2021 |